Pharmesis posted a FY 2025 net loss attributable to shareholders of RMB 4.3 million, versus a net profit a year earlier, as revenue fell to RMB 43.8 million (down 35.3%). The company reported an operating loss of RMB 3.3 million and a gross profit of RMB 15.8 million (down 34.4%), while other income was RMB 2.0 million (down 72.3%). Basic and diluted loss per share was 13.6 RMB cents. For 2H 2025, Pharmesis recorded a net loss attributable to shareholders of RMB 2.9 million and revenue of RMB 16.6 million (down 62.2%), with the decline mainly attributed to the absence of revenue from the Traditional Chinese procurement segment, which contributed RMB 28.9 million in 2H 2024. Other income in 2H 2025 was RMB 1.9 million (down 74.6%), and management said the prior-year period included a one-off reversal of impairment relating to the JiangYou Factory. By segment for FY 2025, external customer revenue was RMB 2.8 million from Western drugs/TCH Procurement, RMB 14.4 million from TCM formulated drugs and IP Rental, and RMB 26.5 million from Distribution. The company cited higher sales of Er Ding driving non-prescribed drugs revenue and higher sales of ATT lifting prescribed drugs revenue. A cash dividend of 1 Singapore cent per share was declared as an interim special 20th anniversary dividend, with payment date and books closure date to be announced later. As at 31 December 2025, Pharmesis had cash and cash equivalents of RMB 4.3 million and bank borrowings of RMB 15.0 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmesis International Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: 4S45ARHV40JETGY3) on February 27, 2026, and is solely responsible for the information contained therein.